Results 21 to 30 of about 2,733,451 (251)

Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19

, 2023
Creating an effective and safe vaccine is critical to fighting the coronavirus infection successfully. Several types of COVID-19 vaccines exist, including inactivated, live attenuated, recombinant, synthetic peptide, virus-like particle-based, DNA and ...
Aziz Nakhanov, Sergazy Nurabayev, Lespek Kutumbetov, Aibol Terebay, Kuanysh Jekebekov, Ainur Nurpeisova, Zhandos Abay, Markhabat Kassenov, Aslan Kerimbayev, Nurika Assanzhanova, Olga Chervyakova, Syrym Kopeyev, Gulnur Nakhanova, Elina Kalimolda, Sabina Moldagulova, Sandugash Sadikaliyeva, Kamshat Shorayeva, Aisha Issabek, Kunsulu Zakarya, Ali Tulendibayev, Yergali Abduraimov, Mukhit Orynbayev, Zharkinay Absatova   +22 more
core   +1 more source

The use of a computerized database to monitor vaccine safety in Viet Nam. [PDF]

, 2005
Health information systems to monitor vaccine safety are used in industrialized countries to detect adverse medical events related to vaccinations or to prove the safety of vaccines. There are no such information systems in the developing world, but they
Ali, Mohammad, Canh, Gia Do, Park, Jin-Kyung, Minh, Tan Truong, Clemens, John D, Thiem, Dinh Vu, von Seidlein, Lorenz, Tho, Huu Le, Vaccine Safety Datalink Group, Trach, Duc Dang   +9 more
core   +2 more sources

COVID-19 vaccine safety

Revista Peruana de Medicina Experimental y Salud Pública, 2021
The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic.
Nataniel Aldo Chaparro Mérida, Dayany Moreno Samper, Alex Omar Franco Lacato   +2 more
doaj   +1 more source

Safety of Vaccination within First Year of Life—The Experience of One General Medicine Center

Children, 2023
Vaccines represent an important preventive strategy in paediatric populations, but the rate of vaccination has been constantly declining in the last decade.
Claudia Felicia Pop, Petronela Coblisan, Ligia Capalna, Paraschiva Cherecheș Panța, Anca Dana Buzoianu, Ioana Corina Bocsan   +5 more
doaj   +1 more source

Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline

Frontiers in Public Health, 2022
Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Victoria's vaccine safety service for reporting adverse events following immunisation (AEFI), has provided integrated spontaneous surveillance and clinical services for ...
Ingrid Laemmle-Ruff, Georgina Lewis, Hazel J. Clothier, Hazel J. Clothier, Hazel J. Clothier, Gerardo Luis Dimaguila, Gerardo Luis Dimaguila, Michelle Wolthuizen, Jim Buttery, Jim Buttery, Jim Buttery, Jim Buttery, Nigel W. Crawford, Nigel W. Crawford, Nigel W. Crawford   +14 more
doaj   +1 more source

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. [PDF]

, 2011
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.\ud \ud METHODS\ud \ud From March 2009 through January 2011, we enrolled 15,460 ...
Machera, Francisca, Abdulla, Salim, Sillman, Marla, Maingi, Charity, Aide, Pedro, Kremsner, Peter Gottfried, Conzelmann, Cornelia, Adjei, George, Abdul, Omari, Leach, Amanda, Methogo, Barbara Gaelle Nfono Ondo, Bejon, Philip, Gondi, Stacey, Chome, Nelecy, Doucka, Yannick, Aponte, John J, Guerra, Yolanda, Chandramohan, Daniel, null null, Jones, David, Liheluka, Edwin, Loucq, Christian, Omoto, Jackton, Nyakuipa, Dalitso, Flamen, Arnaud, Jongert, Erik, Otieno, Walter, Bassat, Quique, Mordmüller, Benjamin, Slutsker, Laurence, Agyekum, Alex, Ofori-Anyinam, Opokua, Hamad, Ali Said, Wasuna, Ruth, Vansadia, Preeti, Lanaspa, Miguel, Drakeley, Chris, Kaboré, William, Asante, Isaac, Gesase, Samwel, Cohen, Joe, Shubis, Kafuruki, Ogutu, Bernhards, Agnandji, Selidji Todagbe, Otieno, Lucas, Sambian, David, Ansong, Daniel, Lell, Bertrand, Awino, Norbert, Gitaka, Jesse, Carter, Terrell, Juma, Omar, Shomari, Mwanajaa, Hoffman, Irving, Mtoro, Ali, Schellenberg, David, Quelhas, Diana, Radford, Afiya, Minja, Rose, Kerubo, Christine, Theander, Thor, Ahmed, Saumu, Odero, Chris, Vekemans, Johan, Nkomo, Ruthendo, Muturi-Kioi, Vincent, Mvalo, Tisungane, RTS,S Clinical Trials Partnership, Tsofa, Benjamin, Dosoo, David, Ouédraogo, Jean Bosco, Mwangoka, Grace, Rettig, Theresa, Sorgho, Hermann, Ouédraogo, Sayouba, Osei-Kwakye, Kingsley, Agbenyega, Tsiri, Owira, Victorine, Issifou, Saadou, Kariuki, Simon, Oneko, Martina, Otieno, Kephas, Olotu, Ally, Lapierre, Didier, Fernandes, José Francisco, Ali, Ali Mohammed, Boahen, Owusu, Onyango, Agnes Akoth, Sylverken, Justice, Hamel, Mary J, Macete, Eusébio, Asante, Kwaku Poku, Owusu-Agyei, Seth, Lemnge, Martha, Ayamba, Samuel, Msika, Albans, Kayan, Kingsley, Alonso, Pedro, Kamthunzi, Portia, Otieno, Allan, Ballou, W Ripley, Nekoye, Otsyula, Lievens, Marc, Abossolo, Béatrice Peggy, Mandjate, Sofia, Marsh, Kevin, Urassa, Alwisa Martin, Mahende, Coline, Bawa, John, Sandrine, Yara, Akoo, Pauline, Adjei, Samuel, Njuguna, Patricia, Jumbe, Allan, Williamson, John, Leboulleux, Didier, Greenwood, Brian, Malabeja, Anangisye, Chilengi, Roma, Nhamuave, Arlindo, Guiguemdé, Robert Tinga, Tinto, Halidou, Tahita, Marc Christian, Martinson, Francis, Kilavo, Hassan, Lusingu, John, Boateng, Harry Owusu, Chintedza, Joseph, Soulanoudjingar, Solange Solmeheim, Lang, Trudie, Sacarlal, Jahit, Bruls, Myriam, The RTS, S. Clinical Trials Partnership, Sykes, Alma, Owusu, Larko, Tanner, Marcel, Laserson, Kayla F, Peshu, Norbert, Savarese, Barbara, Owusu-Ofori, Ruth, Valea, Innocent, D'Alessandro, Umberto, Salim, Nahya   +142 more
core   +1 more source

A social media intervention for communicating vaccine safety in low- and middle-income countries: protocol for a pilot study

Frontiers in Public Health, 2023
Vaccine safety is a concern that continues to drive hesitancy and refusal in populations in low-and-middle income countries (LMICs). Communicating about vaccine safety is a strategy that can successfully change personal and community perceptions and ...
Lucie Marisa Bucci, Smaragda Lamprianou, Francesco Gesualdo, Alberto E. Tozzi, Tala Ghalayini, Isabelle Sahinovic, Shanthi Pal   +6 more
doaj   +1 more source

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective

Vaccines
Vaccine marketing authorization holders (MAHs) are responsible for the conduction of global vaccine pharmacovigilance on their vaccine products. A safety signal is detected when a new adverse event (AE) or aspect of an AE occurs after exposure to the ...
Maria Maddalena Lino, Susan Mather, Marianna Trani, Yan Chen, Patrick Caubel, Barbara De Bernardi   +5 more
doaj   +1 more source

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. [PDF]

, 2009
BACKGROUND: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown ...
Gesase Samwel, Druilhe, Pierre, Chilengi Roma, Roma Chilengi, Method D Segeja, Seth, Misago, Msham Salum, Francis Filbert, Lemnge, Martha, Samwel Sembuche, Salum Msham, Noor Ramadhani, Cousens Simon, Sembuche, Samwel, Minja Daniel, Martha Lemnge, Simon Cousens, Samuel Bosomprah, Chilengi, Roma, Samwel Gesase, Lusingu, John PA, Gesase, Samwel, John PA Lusingu, Rutta, Acleus, Bosomprah Samuel, Cousens, Simon, Ramadhani Noor, Acleus Rutta, Pierre Druilhe, Seth Misago, Segeja Method D, Minja, Daniel, Msham, Salum, Druilhe Pierre, Daniel Minja, Francis, Filbert, Noor, Ramadhani, Lemnge Martha, Bosomprah, Samuel, Lusingu John PA, Rutta Acleus, Misago Seth, Segeja, Method D, Sembuche Samwel, Filbert Francis   +44 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source